[go: up one dir, main page]

MA34284B1 - Indoles - Google Patents

Indoles

Info

Publication number
MA34284B1
MA34284B1 MA35415A MA35415A MA34284B1 MA 34284 B1 MA34284 B1 MA 34284B1 MA 35415 A MA35415 A MA 35415A MA 35415 A MA35415 A MA 35415A MA 34284 B1 MA34284 B1 MA 34284B1
Authority
MA
Morocco
Prior art keywords
indoles
useful
formula
relates
present
Prior art date
Application number
MA35415A
Other languages
English (en)
Inventor
James Brackley
Joelle Lorraine Burgess
Seth Grant
Neil Johnson
Steven D Knight
Louis Lafrance
William H Miller
Kenneth Newlander
Stuart Romeril
Meagan B Rouse
Xinrong Tian
Sharad Kumar Verma
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MA34284B1 publication Critical patent/MA34284B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des indoles de formule (I) dont les divers groupes sont définis dans la présente et qui sont utiles pour traiter les cancers.
MA35415A 2010-05-07 2011-05-05 Indoles MA34284B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33230910P 2010-05-07 2010-05-07
PCT/US2011/035336 WO2011140324A1 (fr) 2010-05-07 2011-05-05 Indoles

Publications (1)

Publication Number Publication Date
MA34284B1 true MA34284B1 (fr) 2013-06-01

Family

ID=44904072

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35415A MA34284B1 (fr) 2010-05-07 2011-05-05 Indoles

Country Status (35)

Country Link
US (5) US8536179B2 (fr)
EP (2) EP3246027A1 (fr)
JP (1) JP5864545B2 (fr)
KR (1) KR20130062290A (fr)
CN (1) CN102970869B (fr)
AU (1) AU2011248068B2 (fr)
BR (1) BR112012028556A2 (fr)
CA (1) CA2798622C (fr)
CL (1) CL2012003110A1 (fr)
CR (1) CR20120565A (fr)
CY (1) CY1119006T1 (fr)
DK (1) DK2566327T3 (fr)
DO (1) DOP2012000282A (fr)
EA (1) EA023788B1 (fr)
ES (1) ES2627085T3 (fr)
HR (1) HRP20170736T1 (fr)
HU (1) HUE034787T2 (fr)
IL (1) IL222878A (fr)
LT (1) LT2566327T (fr)
MA (1) MA34284B1 (fr)
ME (1) ME02757B (fr)
MX (1) MX2012012966A (fr)
MY (1) MY184101A (fr)
NZ (1) NZ603454A (fr)
PE (1) PE20130647A1 (fr)
PH (1) PH12012502194A1 (fr)
PL (1) PL2566327T3 (fr)
PT (1) PT2566327T (fr)
RS (1) RS55874B1 (fr)
SG (1) SG185431A1 (fr)
SI (1) SI2566327T1 (fr)
SM (1) SMT201700245T1 (fr)
UA (1) UA110112C2 (fr)
WO (1) WO2011140324A1 (fr)
ZA (1) ZA201208447B (fr)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2566328B1 (fr) 2010-05-07 2015-03-04 GlaxoSmithKline LLC Indazoles
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012075080A1 (fr) * 2010-12-01 2012-06-07 Glaxosmithkline Llc Indoles
WO2012118812A2 (fr) 2011-02-28 2012-09-07 Epizyme, Inc. Composés hétéroaryles bicycliques substitués condensés en 6,5
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
AU2013203641B2 (en) * 2011-04-13 2014-08-21 Epizyme, Inc. Aryl-or heteroaryl-substituted benzene compounds
CN103987842A (zh) * 2011-09-30 2014-08-13 葛兰素史密斯克莱有限责任公司 治疗癌症的方法
US9242962B2 (en) 2011-11-04 2016-01-26 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
US9206128B2 (en) 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013075084A1 (fr) * 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
JP5977837B2 (ja) 2011-12-21 2016-08-24 ノヴィラ・セラピューティクス・インコーポレイテッド Ｂ型肝炎抗ウイルス剤
CA2862289C (fr) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulateurs d'enzymes de modification par methylation, leurs compositions et utilisations
JP6321619B2 (ja) 2012-03-12 2018-05-09 エピザイム インコーポレイテッド ヒトｅｚｈ２の阻害剤およびその使用方法
EP2828250B1 (fr) 2012-03-19 2021-03-10 Imperial College Innovations Limited Composes de quinazoline et leur application therapeutque
PL2836491T3 (pl) * 2012-04-13 2017-08-31 Epizyme, Inc. Postać soli inhibitora ludzkiej metylotransferazy histonowej EZH2
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
CN104769428A (zh) 2012-06-14 2015-07-08 怀特海德生物医学研究所 评价化学实体与其靶标分子之间的相互作用的全基因组方法
NZ743463A (en) 2012-08-28 2019-09-27 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
CA2884848C (fr) 2012-09-28 2017-08-22 Pfizer Inc. Composes de benzamide et heterobenzamide
IL308613A (en) 2012-10-15 2024-01-01 Epizyme Inc Cancer treatment methods
US9006242B2 (en) 2012-10-15 2015-04-14 Epizyme, Inc. Substituted benzene compounds
RU2015127822A (ru) * 2012-12-13 2017-01-16 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Ингибиторы энхансера гомолога 2 белка zeste
WO2014100080A1 (fr) * 2012-12-19 2014-06-26 Glaxosmithkline Llc Combinaison
EP2935264B1 (fr) 2012-12-21 2017-10-18 Epizyme, Inc. Composés hétéroaryles bicycliques 1,4-pyridone
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
ME02730B (fr) * 2013-02-11 2017-10-20 Constellation Pharmaceuticals Inc Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
MX366123B (es) 2013-02-28 2019-06-27 Janssen Sciences Ireland Uc Sulfamoil-arilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis b.
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
WO2014153208A1 (fr) 2013-03-14 2014-09-25 Epizyme, Inc. Inhibiteurs d'arginine méthyltransférase et leurs utilisations
US20160039767A1 (en) 2013-03-14 2016-02-11 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
BR112015022785A2 (pt) 2013-03-14 2017-07-18 Epizyme Inc composto; composição farmacêutica; kit ou artigo farmacêutico embalado; método de inibição de uma arginina metil transferase (rmt); método de modulação da expressão genética; método de modulação da transcrição; e método de tratamento de um distúrbio mediado por rmt
US9447079B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. PRMT1 inhibitors and uses thereof
EP2970220A2 (fr) 2013-03-14 2016-01-20 Epizyme, Inc. Inhibiteurs de l'arginine méthyltransférase et utilisations de ceux-ci
HK1220916A1 (zh) 2013-03-14 2017-05-19 基因泰克公司 治疗癌症和预防癌症药物抗性的方法
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9365527B2 (en) 2013-03-14 2016-06-14 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9133189B2 (en) 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9023883B2 (en) 2013-03-14 2015-05-05 Epizyme, Inc. PRMT1 inhibitors and uses thereof
CA2903264A1 (fr) 2013-03-14 2014-11-06 Epizyme, Inc. Inhibiteurs de l'arginine methyltransferase et utilisations de ceux-ci
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2014155301A1 (fr) * 2013-03-26 2014-10-02 Piramal Enterprises Limited Composés bicycliques substitués utilisés comme inhibiteurs d'ezh2
EA027068B1 (ru) 2013-04-03 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
EA030196B1 (ru) * 2013-04-30 2018-07-31 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Ингибиторы энхансера zeste гомолога 2
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
CN105960400B (zh) 2013-05-17 2019-05-31 爱尔兰詹森科学公司 氨磺酰基噻吩酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
AU2014276417B2 (en) * 2013-06-06 2016-11-24 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of Zeste Homolog 2 inhibitors
US9556157B2 (en) 2013-07-10 2017-01-31 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
PL3024819T3 (pl) 2013-07-25 2018-08-31 Janssen Sciences Ireland Uc Pochodne piroloamidowe podstawione glioksamidem i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B
EP3033334A1 (fr) * 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Dérivés d'indole utilisés en tant que modulateurs d'enzymes de modification du méthyle, compositions et utilisations associées
EA038869B1 (ru) 2013-10-16 2021-10-29 Эпизим, Инк. Кристаллические формы гидрохлорида n-((4,6-диметил-2-оксо-1,2-дигидропиридин-3-ил)метил)-5-(этил(тетрагидро-2h-пиран-4-ил)амино)-4-метил-4'-(морфолинометил)-[1,1'-бифенил]-3-карбоксамида, фармацевтические композиции на их основе и способы их применения
EP3060547B1 (fr) 2013-10-23 2017-10-11 Janssen Sciences Ireland UC Dérivés de carboxamide et leur utilisation comme médicaments pour le traitement de l'hépatite b
WO2015077194A1 (fr) * 2013-11-22 2015-05-28 Bristol-Myers Squibb Company Inhibiteurs de la lysine méthyltransférase
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US20150216938A1 (en) 2014-02-05 2015-08-06 Novira Therapeutics Inc. Combination therapy for treatment of hbv infections
CN110483484A (zh) 2014-02-06 2019-11-22 爱尔兰詹森科学公司 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
WO2015120372A2 (fr) * 2014-02-10 2015-08-13 University Of Rochester Compositions et méthodes d'inhibition de ezh2 pour traiter des maladies cardiovasculaires
EP3111222A1 (fr) 2014-02-26 2017-01-04 Glaxosmithkline Intellectual Property (No. 2) Limited Méthodes de traitement de patients atteints de cancer réagissant à l'inhibiteur d'ezh2 gsk126
EP3119390A4 (fr) * 2014-03-21 2017-09-20 Glaxosmithkline Intellectual Property (No. 2) Limited Méthodes de traitement du cancer
CN105037360B (zh) * 2014-04-28 2016-08-17 四川大学 吡啶酮衍生物及其制备方法和用途
CN105017221B (zh) * 2014-04-30 2019-05-28 中国医学科学院药物研究所 苯并咪唑衍生物及其制法和药物组合物与用途
GEAP201814347A (en) 2014-06-17 2018-08-10 Pfizer Substituted dihydroisoquinoline compounds
WO2015200650A1 (fr) * 2014-06-25 2015-12-30 Epizyme, Inc. Composés hétéroaryles bicycliques fusionnés en 6,5 ou benzènes substitués
CA2965729A1 (fr) * 2014-10-28 2016-05-06 Glaxosmithkline Intellectual Property (No.2) Limited Inhibiteurs d'ezh2 (enhancer of zeste homolog 2)
CN107105651A (zh) 2014-11-06 2017-08-29 达纳-法伯癌症研究所股份有限公司 Ezh2抑制剂及其用途
AR102767A1 (es) 2014-12-05 2017-03-22 Lilly Co Eli Inhibidores de ezh2
WO2016102493A1 (fr) * 2014-12-22 2016-06-30 Bayer Pharma Aktiengesellschaft Inhibiteurs d'ezh2 de type imidazopyridine
PE20171307A1 (es) * 2014-12-23 2017-09-05 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos
US20180271857A1 (en) 2014-12-23 2018-09-27 University Of Copenhagen Treatment of cancer by inhibiting ezh2 activity
CN107847762A (zh) 2015-03-19 2018-03-27 诺维拉治疗公司 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法
EP3283502A4 (fr) 2015-04-07 2019-04-03 The General Hospital Corporation Procédés de réactivation de gènes sur le chromosome x inactif
MX387885B (es) * 2015-06-10 2025-03-19 Epizyme Inc Inhibidores de ezh2 para tratar linfomas.
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017035234A1 (fr) 2015-08-24 2017-03-02 Epizyme, Inc. Méthode de traitement du cancer
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2017040190A1 (fr) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Formes cristallines de (r)-n-((4-méthoxy-6-méthyl-2-oxo-1,2-dihydropyridin-3-yl)méthyl)-2-méthyl-1-(1-(1-(2,2,2-trifluoroéthyl)pipéridin-4-yl)éthyl)-1h-indole-3-carboxamide
HK1259410A1 (zh) 2015-09-29 2019-11-29 诺维拉治疗公司 乙型肝炎抗病毒剂的晶体形式
WO2017062495A2 (fr) 2015-10-06 2017-04-13 Epizyme, Inc. Procédé de traitement d'un médulloblastome avec un inhibiteur d'ezh2
US20180321256A1 (en) 2015-11-05 2018-11-08 Epizyme, Inc. Flow cytometry for monitoring histone h3 methylation status
EP3378859B1 (fr) * 2015-11-19 2019-10-30 Jiangsu Hengrui Medicine Co., Ltd. Dérivé du benzofurane, son procédé de préparation et son utilisation en médecine
JP2019503391A (ja) 2016-01-29 2019-02-07 エピザイム，インコーポレイティド 癌を処置するための併用療法
JP7174408B2 (ja) 2016-02-10 2022-11-17 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ 肝線維症のモデル系ならびにその作製および使用方法
EP3429571B1 (fr) 2016-03-15 2025-10-08 Oryzon Genomics, S.A. Combinaisons d'inhibiteurs de lsd1 pour une utilisation dans le traitement de maladies néoplasiques
CN109640980A (zh) 2016-04-15 2019-04-16 诺维拉治疗公司 包含壳体装配抑制剂的组合和方法
WO2017184999A1 (fr) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Inhibiteurs d'ezh2 et leurs utilisations
CN105777718B (zh) * 2016-04-27 2019-03-19 上海应用技术学院 潜在ezh2小分子抑制剂及其合成方法
WO2017192290A1 (fr) 2016-05-04 2017-11-09 The Wistar Institute Of Anatomy And Biology Méthodes de traitement de cancers surexprimant la carm1 comprenant des inhibiteurs d'ezh2 et des médicaments anticancéreux à base de platine
EP3471830A4 (fr) 2016-06-17 2020-02-26 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer
WO2017221092A1 (fr) * 2016-06-20 2017-12-28 Novartis Ag Composés de triazolopyridine et leurs utilisations
CN107573327B (zh) * 2016-07-05 2020-03-31 四川大学 吲唑-甲酰胺-吡啶酮衍生物及其制备方法和用途
CN107573336B (zh) * 2016-07-05 2021-01-19 四川大学 苯并杂环-甲酰胺-吡啶酮衍生物及其制备方法和用途
US10457640B2 (en) 2016-10-19 2019-10-29 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of EZH2
CN108698990B (zh) * 2016-11-11 2021-07-30 上海海雁医药科技有限公司 砜基取代的苯并杂环衍生物、其制法与医药上的用途
CN108699002B (zh) * 2016-11-11 2021-11-09 上海海雁医药科技有限公司 1,5,7-三取代的异喹啉衍生物、其制法与医药上的用途
JP7208898B2 (ja) 2016-12-02 2023-01-19 エピザイム，インコーポレイティド 癌を処置するための併用療法
TW201831181A (zh) * 2017-01-19 2018-09-01 日商第一三共股份有限公司 用以用於治療ｈｔｌｖ－１相關脊髓病之醫藥組成物
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
WO2018183885A1 (fr) 2017-03-31 2018-10-04 Epizyme, Inc. Multithérapie pour le traitement du cancer
US20230201212A1 (en) 2017-06-13 2023-06-29 Epizyme, Inc. Inhibitors of ezh2 and methods of use thereof
JP7201400B2 (ja) 2017-11-14 2023-01-10 ファイザー・インク Ｅｚｈ２阻害剤組合せ療法
BR112020015583B1 (pt) 2018-01-31 2022-12-06 Mirati Therapeutics, Inc Composto, composição farmacêutica e seu uso para tratar câncer
CN110229151B (zh) * 2018-03-06 2021-09-10 上海海和药物研究开发股份有限公司 吲嗪类化合物、其制备方法及用途
CA3090125A1 (fr) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Schema posologique de modulateur d'assemblage de capside
EP3823671B1 (fr) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition de sous-unités de prc2 permettant de traiter des troubles oculaires
CA3106589A1 (fr) 2018-07-27 2020-01-30 Suzhou Sinovent Pharma Co., Ltd. Compose de benzene polysubstitue et son procede de preparation et son utilisation
JP2022521081A (ja) 2019-02-22 2022-04-05 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｈｂｖ感染若しくはｈｂｖ誘導性疾患の治療において有用なアミド誘導体
CN109761960B (zh) * 2019-02-25 2021-08-31 江苏豪森药业集团有限公司 抗耐药抗肿瘤egfr抑制剂的制备方法
WO2020219448A1 (fr) 2019-04-22 2020-10-29 Mirati Therapeutics, Inc. Dérivés de naphtyridine en tant qu'inhibiteurs de prc2
MA55879A (fr) 2019-05-06 2022-03-16 Janssen Sciences Ireland Unlimited Co Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
EP3980422A1 (fr) 2019-06-05 2022-04-13 Mirati Therapeutics, Inc. Dérivés d'imidazo [1,2-c]pyrimidine utilisés comme inhibiteurs de prc2 pour le traitement du cancer
EP4003532B1 (fr) 2019-07-24 2024-09-04 Constellation Pharmaceuticals, Inc. Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide
JP2022545467A (ja) 2019-08-22 2022-10-27 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法
US12006232B2 (en) 2020-06-09 2024-06-11 Rapid Water Technology LLC Water processing apparatus
WO2022133046A2 (fr) * 2020-12-16 2022-06-23 Ifm Due, Inc. Composés et compositions pour traiter des états pathologiques associés à une activité de sting
CN113307765A (zh) * 2021-05-24 2021-08-27 上海泰坦科技股份有限公司 吡啶甲胺类化合物及其制备方法
US20240350508A1 (en) 2021-08-25 2024-10-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ezh2 inhibitors for the treatment of aortic valve stenosis
US20250049802A1 (en) 2021-12-14 2025-02-13 Pfizer Inc. Combination therapies and uses for treating cancer
TW202400140A (zh) 2022-04-27 2024-01-01 日商第一三共股份有限公司 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合
CN117088810A (zh) * 2023-06-27 2023-11-21 海南医学院 3-氰基吡啶酮化合物的串联合成方法
CN117362277B (zh) * 2023-10-13 2025-02-11 沈阳药科大学 含咪唑啉酮结构的苯甲酰胺类化合物及其制备方法和应用
CN118745144A (zh) * 2024-06-21 2024-10-08 辽宁大学 新型ezh2抑制剂化合物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2584713B1 (fr) * 1985-07-11 1988-09-09 Roussel Uclaf Nouveaux derives de l'indole carboxamide, leurs sels, procede et intermediaires de preparation, application a titre de medicaments et compositions les renfermant
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
WO2004112719A2 (fr) * 2003-06-19 2004-12-29 Smithkline Beecham Corporation Composes chimiques
PE20060748A1 (es) 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
EP2114877B1 (fr) * 2007-02-26 2012-12-26 Merck Canada Inc. Dérivés d'indole et indoline cyclopropyl amide comme antagonistes du récepteur ep4
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
US20090012031A1 (en) * 2007-07-03 2009-01-08 The Regents Of The University Of Michigan EZH2 Cancer Markers
AR070398A1 (es) 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
SG10201506608RA (en) 2008-09-26 2015-09-29 Agency Science Tech & Res 3-deazaneplanocin derivatives
JP5889875B2 (ja) * 2010-05-07 2016-03-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ アザインダゾール
EP2566328B1 (fr) * 2010-05-07 2015-03-04 GlaxoSmithKline LLC Indazoles
WO2012118812A2 (fr) * 2011-02-28 2012-09-07 Epizyme, Inc. Composés hétéroaryles bicycliques substitués condensés en 6,5

Also Published As

Publication number Publication date
US8975291B2 (en) 2015-03-10
PT2566327T (pt) 2017-05-26
JP2013525498A (ja) 2013-06-20
BR112012028556A2 (pt) 2014-04-01
HUE034787T2 (en) 2018-02-28
KR20130062290A (ko) 2013-06-12
EP3246027A1 (fr) 2017-11-22
CR20120565A (es) 2013-02-20
AU2011248068A1 (en) 2012-12-20
IL222878A (en) 2016-11-30
ME02757B (fr) 2018-01-20
US9402836B2 (en) 2016-08-02
WO2011140324A1 (fr) 2011-11-10
US8536179B2 (en) 2013-09-17
JP5864545B2 (ja) 2016-02-17
RS55874B1 (sr) 2017-08-31
US20150313887A1 (en) 2015-11-05
LT2566327T (lt) 2017-05-25
ES2627085T3 (es) 2017-07-26
EP2566327B1 (fr) 2017-03-29
DK2566327T3 (en) 2017-05-08
SG185431A1 (en) 2012-12-28
US9649307B2 (en) 2017-05-16
PE20130647A1 (es) 2013-06-26
US20150141436A1 (en) 2015-05-21
EA023788B1 (ru) 2016-07-29
UA110112C2 (uk) 2015-11-25
SI2566327T1 (sl) 2017-07-31
MX2012012966A (es) 2013-01-22
PH12012502194A1 (en) 2014-09-05
EA201291194A1 (ru) 2013-04-30
HRP20170736T1 (hr) 2017-07-28
IL222878A0 (en) 2012-12-31
MY184101A (en) 2021-03-18
ZA201208447B (en) 2013-07-31
CY1119006T1 (el) 2018-01-10
CN102970869B (zh) 2014-07-16
AU2011248068B2 (en) 2014-09-11
CA2798622A1 (fr) 2011-11-10
US20130053397A1 (en) 2013-02-28
CN102970869A (zh) 2013-03-13
EP2566327A4 (fr) 2013-12-11
US20160296518A1 (en) 2016-10-13
CA2798622C (fr) 2016-11-15
PL2566327T3 (pl) 2017-09-29
NZ603454A (en) 2014-06-27
US20130345200A1 (en) 2013-12-26
DOP2012000282A (es) 2013-02-28
SMT201700245T1 (it) 2017-07-18
US9114141B2 (en) 2015-08-25
EP2566327A1 (fr) 2013-03-13
CL2012003110A1 (es) 2013-03-08

Similar Documents

Publication Publication Date Title
MA34284B1 (fr) Indoles
EA201270149A1 (ru) Ингибиторы bace
EA201171367A1 (ru) Винилиндазолильные соединения
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
EA200971078A1 (ru) Противовирусные соединения
EA201200999A1 (ru) Способы лечения рака молочной железы
EA201691327A1 (ru) Полиморфные формы (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
EA201190259A1 (ru) Противовирусные соединения
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
EA201890333A1 (ru) Противовирусные соединения
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
EA201590171A1 (ru) ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b
EA201201000A1 (ru) Способы лечения колоректального рака
EA201290642A1 (ru) Соединения и способы
MA39172B1 (fr) Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
EA201070256A1 (ru) Способ и промежуточные соединения для получения ингибиторов интегразы
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201270255A1 (ru) 5-фтор-2-оксопиримидин-1(2h)-карбоксилатные производные
EA201200247A1 (ru) Новые азагетероциклические соединения
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
EA201170997A1 (ru) Производные индола в качестве противораковых агентов
EA201170831A1 (ru) Аминопиразольное соединение